

Franz H Messerli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4362416/franz-h-messerli-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200
papers

15,497
citations

57
h-index

123
g-index

234
ext. papers

19,120
ext. citations

8.5
avg, IF

6.8
L-index

#	Paper	IF	Citations
200	Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?. <i>Circulation</i> , 2022 , 145, 413-415	16.7	1
199	Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?. <i>Global Heart</i> , 2022 , 17, 17	2.9	0
198	Safety and Efficacy of Thiazide Diuretics in Hypertension.. <i>American Journal of Medicine</i> , 2022 , 135, e109	2.4	
197	Salt consumption at a population level remains remarkably steady over time. <i>European Heart Journal</i> , 2021 , 42, 2134	9.5	1
196	Alcohol and atrial fibrillation: not all drinks are created equal. <i>European Heart Journal</i> , 2021 , 42, 2506	9.5	2
195	Ivabradine in POTS. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 3141-3142	15.1	0
194	Lowering systolic blood pressure to 120 mmHg or The Lancet's true grit. <i>European Heart Journal</i> , 2021 , 42, 2052-2059	9.5	1
193	Sodium intake, life expectancy, and all-cause mortality. <i>European Heart Journal</i> , 2021 , 42, 2103-2112	9.5	14
192	Chlorthalidone versus hydrochlorothiazide: major cardiovascular events, blood pressure, left ventricular mass, and adverse effects. <i>Journal of Hypertension</i> , 2021 , 39, 1254-1260	1.9	3
191	Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. <i>Journal of Hypertension</i> , 2021 , 39, 784-794	1.9	17
190	Social media and predictive analysis regarding dietary approaches to stop hypertension. <i>Progress in Cardiovascular Diseases</i> , 2021 , 68, 88-90	8.5	
189	Soluble fms-like tyrosine kinase 1 (sFlt-1): A novel biochemical marker for acute fatty liver of pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021 , 100, 1876-1884	3.8	1
188	Reply. <i>Journal of Hypertension</i> , 2021 , 39, 1726-1727	1.9	
187	Cerebrotoxicity of antihypertensive therapy in the UK Biobank Cohort Study. <i>European Heart Journal</i> , 2021 , 42, 4282	9.5	1
186	Importance of pulse pressure at low systolic blood pressure. <i>European Heart Journal</i> , 2021 ,	9.5	1
185	Non-invasive pulmonary artery pressure estimation by electrical impedance tomography in a controlled hypoxemia study in healthy subjects. <i>Scientific Reports</i> , 2020 , 10, 21462	4.9	5
184	Coronavirus disease 2019 (COVID-19) and cardiovascular risk: A meta-analysis. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 527-528	8.5	10

183	Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 682-689	8.5	126
182	Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. <i>JAMA Cardiology</i> , 2020 , 5, 745-747	16.2	158
181	Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?. <i>Journal of the American Heart Association</i> , 2020 , 9, e016509	6	159
180	Is diabetes still a compelling indication for renin-angiotensin-aldosterone system inhibitors?. <i>Cleveland Clinic Journal of Medicine</i> , 2020 , 87, 9	2.8	
179	Implications of Guideline Updates for the Management of Apparent Treatment Resistant Hypertension in the United States (A NCDR Research to Practice [R2P] Project). <i>American Journal of Cardiology</i> , 2020 , 125, 63-67	3	1
178	Interamerican Society of Cardiology (IASC) position statement: Chlorthalidone vs. thiazide-diuretics. <i>International Journal of Cardiology: Hypertension</i> , 2020 , 7, 100054	1.6	1
177	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. <i>European Heart Journal</i> , 2020 , 41, 3363-3373	9.5	33
176	Chlorthalidone and Hydrochlorothiazide for Treatment of Patients With Hypertension. <i>JAMA Internal Medicine</i> , 2020 , 180, 1133	11.5	1
175	Letter by Messerli et al Regarding Article, "Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort". <i>Circulation</i> , 2020 , 142, e27-e28	16.7	0
174	COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations. <i>Circulation</i> , 2020 , 141, 2042-2044	16.7	28
173	Risk Factor Variability and Cardiovascular Outcome: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2596-2603	15.1	33
172	Letter by Messerli et al Regarding Article "Early Life Factors and Longitudinal Blood Pressure Trajectories Are Associated With Elevated Blood Pressure in Early Adulthood: BT20 Cohort". <i>Hypertension</i> , 2019 , 73, e83	8.5	1
171	The alcohol blood pressure paradox. <i>European Heart Journal</i> , 2019 , 40, 711-712	9.5	4
170	Letter by Messerli and Bangalore Regarding Article, "Association of Blood Pressure Measurements With Peripheral Artery Disease Events". <i>Circulation</i> , 2019 , 139, 1854	16.7	
169	Misconceptions and Facts About Beta-Blockers. <i>American Journal of Medicine</i> , 2019 , 132, 816-819	2.4	9
168	Blood Pressure Variability and Arterial Stiffness-Chicken or Egg?. <i>JAMA Cardiology</i> , 2019 , 4, 1050	16.2	4
167	Renin-Angiotensin-Aldosterone Axis Modulators and Other Vasodilators. <i>Contemporary Cardiology</i> , 2019 , 61-72	0.1	
166	Beta Blockers and Calcium Channel Blockers. <i>Contemporary Cardiology</i> , 2019 , 73-88	0.1	1

165	Postholiday Heart Failure Triggered by Dietary Salt Excess. <i>JAMA Internal Medicine</i> , 2019 , 179, 1006-1007	1.5	
164	How much salt is too much salt?. <i>Anatolian Journal of Cardiology</i> , 2019 , 22, 2-4	0.8	
163	Stable coronary artery disease: are there therapeutic benefits of heart rate lowering?. <i>Journal of Hypertension</i> , 2019 , 37, 1112-1118	1.9	4
162	Systolic Hypertension, Preeclampsia-Related Mortality, and Stroke In California. <i>Obstetrics and Gynecology</i> , 2019 , 134, 880	4.9	2
161	Ultra-high sensitive C-reactive protein during normal pregnancy and in preeclampsia: a pilot study. <i>Journal of Hypertension</i> , 2019 , 37, 1012-1017	1.9	9
160	Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. <i>Journal of Hypertension</i> , 2019 , 37, 2093-2103	1.9	5
159	Changing definition of hypertension in guidelines: how innocent a number game?. <i>European Heart Journal</i> , 2018 , 39, 2241-2242	9.5	15
158	Hypothyroidism and hypertension: fact or myth?. <i>Lancet, The</i> , 2018 , 391, 29-30	4.0	4
157	The Reply. <i>American Journal of Medicine</i> , 2018 , 131, e27	2.4	
156	Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1474-1482	15.1	135
155	Age, Cardiovascular Risk, and Blood Pressure Target. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 818-819	15.1	
154	Age, Blood Pressure Targets, and Guidelines: Rift Between Those Who Preach, Those Who Teach, and Those Who Treat?. <i>Circulation</i> , 2018 , 138, 128-130	16.7	12
153	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018 , 39, 3021-3104	9.5	3698
152	Salt and heart disease: a second round of "bad science"?. <i>Lancet, The</i> , 2018 , 392, 456-458	4.0	25
151	Alter ego(s) in coronary artery disease: Insights from a recently departed patient. <i>European Heart Journal</i> , 2018 , 39, 3987-3998	9.5	1
150	Reply: What Is the Ideal Blood Pressure Goal for Heart Failure Patients?. <i>JACC: Heart Failure</i> , 2018 , 6, 890	7.9	
149	Association of Assisted Reproductive Technologies With Arterial Hypertension During Adolescence. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1267-1274	15.1	75
148	The oldest old: does hypertension become essential again?. <i>European Heart Journal</i> , 2018 , 39, 3144-3146	9.5	6

147	When Guideline Authors Ignore Their Own Guidelines. <i>Hypertension</i> , 2018 , 72, e19	8.5	
146	Gaisb�k syndrome (polycythemia and hypertension) revisited: results from the national inpatient sample database. <i>Journal of Hypertension</i> , 2018 , 36, 2420-2424	1.9	5
145	Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension. <i>Current Hypertension Reports</i> , 2018 , 20, 75	4.7	43
144	Ivabradine in Coronary Heart Disease-The Emperor Has No Clothes. <i>American Journal of Cardiology</i> , 2017 , 120, e15	3	2
143	Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. <i>American Journal of Medicine</i> , 2017 , 130, 707-719.e8	2.4	105
142	Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 486-493	15.1	80
141	Hypertension control and cardiovascular disease. <i>Lancet, The</i> , 2017 , 389, 153	4.0	6
140	Letter by Messerli et al Regarding Article, "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure". <i>Circulation</i> , 2017 , 135, e45-e46	16.7	6
139	Salt and Blood Pressure: Cutting Through the Scientific Fog. <i>Current Hypertension Reports</i> , 2017 , 19, 47	4.7	1
138	Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>American Journal of Medicine</i> , 2017 , 130, 1325.e1-1325.e12	2.4	11
137	Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction. <i>Circulation</i> , 2017 , 135, 2085-2087	16.7	21
136	Body-Weight Fluctuations and Outcomes in Coronary Disease. <i>New England Journal of Medicine</i> , 2017 , 376, 1332-1340	59.2	150
135	Safety vs Efficacy of Lowering Blood Pressure. <i>JAMA Cardiology</i> , 2017 , 2, 1398-1399	16.2	
134	Heart Failure With Preserved Ejection Fraction: A Late Stage of Hypertensive Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2458	15.1	1
133	Hypothyroidism as a cause of secondary hypertension - Myth dispelled. <i>Journal of the American Society of Hypertension</i> , 2017 , 11, 615		
132	Renal denervation: will the Phoenix rise from the ashes?. <i>European Heart Journal</i> , 2017 , 38, 3321-3323	9.5	1
131	The Reply. <i>American Journal of Medicine</i> , 2017 , 130, e321	2.4	
130	Reply: Hypertension Treatment in the Elderly: Individualized Target or Intensive Blood Pressure Lowering?. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 510	15.1	4

129	The Transition From Hypertension to Heart Failure: Contemporary Update. <i>JACC: Heart Failure</i> , 2017 , 5, 543-551	7.9	160
128	Reply. <i>Journal of Hypertension</i> , 2017 , 35, 2327-2328	1.9	
127	Reply: Diabetic Hypertensives and Diastolic Dysfunction: Use of Calcium-Channel Blockers-A Clinical Concern. <i>JACC: Heart Failure</i> , 2017 , 5, 851	7.9	
126	In polypills, as in any recipe, it's ingredients that matter. <i>Journal of Hypertension</i> , 2017 , 35, 2550	1.9	1
125	Reply: Adequate Blood Pressure Control and Monitoring Acute Kidney Injury in Older Hypertensive Patients. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 120	15.1	2
124	Body-Weight Fluctuations and Outcomes in Coronary Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 95-6	59.2	10
123	Are ACE inhibitors acceptable ingredients in polypills?. <i>Lancet, The</i> , 2017 , 390, 26	4.0	3
122	Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial. <i>American Journal of Cardiology</i> , 2017 , 119, 379-387	3	41
121	Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. <i>BMJ, The</i> , 2017 , 356, j4	5.9	49
120	Meta-Analysis of Randomized Trials on the Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Patients ≥ 5 Years of Age. <i>American Journal of Cardiology</i> , 2016 , 118, 1427-1436	3	9
119	Isolated Systolic Hypertension: An Update After SPRINT. <i>American Journal of Medicine</i> , 2016 , 129, 1251-1258	12.5	59
118	In Reply-The Different Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 972-5	6.4	1
117	Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?. <i>Progress in Cardiovascular Diseases</i> , 2016 , 59, 253-261	8.5	24
116	Cognitive Decline, Blood Pressure Control and Variability: A Relentless Downward Spiral?. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 1160-1161	5.9	
115	Heart rate lowering by beta-blockade and cardiovascular events. <i>Journal of Hypertension</i> , 2016 , 34, 2102-13	1.3	2
114	Adverse effects and tolerability of β blockers. <i>BMJ, The</i> , 2016 , 353, i3142	5.9	3
113	Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 379-389	15.1	57
112	Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. <i>BMJ, The</i> , 2016 , 352, i438	5.9	98

111	Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 51-60	6.4	64
110	Atherosclerotic Renal Artery Stenosis and Hypertension: Pragmatism, Pitfalls, and Perspectives. <i>American Journal of Medicine</i> , 2016 , 129, 635.e5-635.e14	2.4	21
109	The relentless crumbling of the renin-angiotensin system (RAS)-blockade halo. <i>Annals of Translational Medicine</i> , 2016 , 4, 321	3.2	
108	Quo usque tandem abutere, Catilina, patientia nostra?. <i>Swiss Medical Weekly</i> , 2016 , 146, w14344	3.1	0
107	Misconceptions and Facts About Mitral Regurgitation. <i>American Journal of Medicine</i> , 2016 , 129, 919-23	2.4	3
106	Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease. <i>Hypertension</i> , 2016 , 67, 1205-10	8.5	25
105	Reply: Efficacy of Low-Dose Chlorthalidone Versus Hydrochlorothiazide Remains Ambiguous. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 430-1	15.1	1
104	When an Increase in Central Systolic Pressure Overrides the Benefits of Heart Rate Lowering. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 754-62	15.1	45
103	Wilder's principle: pre-treatment value determines post-treatment response. <i>European Heart Journal</i> , 2015 , 36, 576-9	9.5	31
102	Drug induced hypertension--An unappreciated cause of secondary hypertension. <i>European Journal of Pharmacology</i> , 2015 , 763, 15-22	5.3	46
101	Misconceptions and facts about treating hypertension. <i>American Journal of Medicine</i> , 2015 , 128, 450-5	2.4	5
100	Optimal blood pressure targets in 2014 - Does the guideline recommendation match the evidence base?. <i>Hipertension Y Riesgo Vascular</i> , 2015 , 32, 71-82	0.5	
99	Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1539-48	15.1	104
98	Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. <i>European Heart Journal</i> , 2015 , 36, 1967-73	9.5	58
97	Resistant hypertension: what the cardiologist needs to know. <i>European Heart Journal</i> , 2015 , 36, 2686-95	9.5	30
96	Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 193-9	2.3	25
95	Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy. <i>PLoS ONE</i> , 2015 , 10, e0122726	3.7	3
94	Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2015 , 116, 809-17	3	47

93	Futility of Imaging Atherosclerotic Renal Artery Stenosis?. <i>American Journal of Medicine</i> , 2015 , 128, e25	2.4	
92	Secondary arterial hypertension: when, who, and how to screen?. <i>European Heart Journal</i> , 2014 , 35, 1245-54	5.4	173
91	Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial. <i>European Heart Journal</i> , 2014 , 35, 1801-8	9.5	10
90	2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 784-93	15.1	46
89	Clinical outcomes with β -blockers for myocardial infarction: a meta-analysis of randomized trials. <i>American Journal of Medicine</i> , 2014 , 127, 939-53	2.4	163
88	Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. <i>European Heart Journal</i> , 2014 , 35, 1732-42	9.5	22
87	Competing cardiovascular and noncardiovascular risks and longevity in the systolic hypertension in the elderly program. <i>American Journal of Cardiology</i> , 2014 , 113, 676-81	3	8
86	Left-ventricular hypertrophy in obesity. <i>Journal of Hypertension</i> , 2014 , 32, 1542-3	1.9	2
85	Letter by Argulian and Messerli regarding article, "effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial". <i>Circulation</i> , 2014 , 130, e18	16.7	
84	The reply. <i>American Journal of Medicine</i> , 2014 , 127, e19	2.4	
83	Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. <i>American Journal of Medicine</i> , 2014 , 127, 71-81.e1	2.4	60
82	Erythrocyte membrane properties in patients with essential hypertension. <i>Cell Biochemistry and Biophysics</i> , 2013 , 67, 1089-102	3.2	23
81	Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. <i>Heart Failure Reviews</i> , 2013 , 18, 429-37	5	17
80	International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2031-45	15.1	104
79	Efficacy and safety of dual calcium channel blockade for the treatment of hypertension: a meta-analysis. <i>American Journal of Hypertension</i> , 2013 , 26, 287-97	2.3	9
78	Fraudulent data: an apology and the fate of angiotensin receptor blockers. <i>BMJ, The</i> , 2013 , 347, f5549	5.9	1
77	Effect of allopurinol on blood pressure: a systematic review and meta-analysis. <i>Journal of Clinical Hypertension</i> , 2013 , 15, 435-42	2.3	103
76	Diuretic-based regimens for obese patients?. <i>Lancet, The</i> , 2013 , 381, 512-3	4.0	3

75	Is dual renin-angiotensin-system blockade associated with increased risk of stroke?. <i>JACC: Heart Failure</i> , 2013 , 1, 454-7	7.9	
74	Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d'Alembert. <i>European Heart Journal</i> , 2013 , 34, 1095-8	9.5	14
73	Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. <i>BMJ, The</i> , 2013 , 346, f360	5.9	145
72	Chocolate consumption, cognitive function, and Nobel laureates. <i>New England Journal of Medicine</i> , 2012 , 367, 1562-4	59.2	105
71	Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. <i>American Journal of Cardiology</i> , 2012 , 110, 383-91	3	113
70	Drug-induced hypertension: an unappreciated cause of secondary hypertension. <i>American Journal of Medicine</i> , 2012 , 125, 14-22	2.4	166
69	The j-point phenomenon in aggressive therapy of hypertension: new insights. <i>Current Atherosclerosis Reports</i> , 2012 , 14, 124-9	6	15
68	Cardiovascular death and cancer death--competing risk?. <i>American Journal of Cardiology</i> , 2012 , 109, 1687		
67	βBlocker use and clinical outcomes in stable outpatients with and without coronary artery disease. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1340-9	27.4	284
66	Blood pressure and stroke: findings from recent trials. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 114-5	15.1	2
65	Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 590-600	15.1	112
64	Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. <i>American Journal of Medicine</i> , 2011 , 124, 896-9	2.4	45
63	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. <i>Lancet Oncology, The</i> , 2011 , 12, 65-82	21.7	264
62	Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. <i>BMJ, The</i> , 2011 , 342, d2234	5.9	96
61	Trials on the effect of cardiac resynchronization on arterial blood pressure in patients with heart failure. <i>American Journal of Cardiology</i> , 2011 , 107, 561-8	3	14
60	Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome. <i>European Heart Journal</i> , 2011 , 32, 2231-5	9.5	105
59	Hypertension management 2011: optimal combination therapy. <i>European Heart Journal</i> , 2011 , 32, 2499-506	5.6	71
58	Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. <i>Circulation</i> , 2011 , 123, 2799-810, 9 p following 810	16.7	312

57	Beyond salt: lifestyle modifications and blood pressure. <i>European Heart Journal</i> , 2011 , 32, 3081-7	9.5	85
56	J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. <i>European Heart Journal</i> , 2010 , 31, 2897-908	9.5	258
55	The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. <i>European Heart Journal</i> , 2010 , 31, 552-60	9.5	60
54	Of fads, fashion, surrogate endpoints and dual RAS blockade. <i>European Heart Journal</i> , 2010 , 31, 2205-8	9.5	29
53	Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. <i>American Journal of Medicine</i> , 2010 , 123, 719-26	2.4	104
52	Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. <i>American Journal of Medicine</i> , 2010 , 123, 1016-30	2.4	77
51	Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). <i>American Journal of Cardiology</i> , 2010 , 106, 498-503	2.3	26
50	Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark?. <i>Circulation</i> , 2009 , 119, 371-3	16.7	17
49	Angiotensin receptor blockers: baseline therapy in hypertension?. <i>European Heart Journal</i> , 2009 , 30, 2427-30	9.5	23
48	Flash pulmonary edema. <i>Progress in Cardiovascular Diseases</i> , 2009 , 52, 249-59	8.5	51
47	Commentary: counterpoint. Simple-minded antihypertensive treatment: of assumptions, potpourri, and sausages. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 702-6	2.3	1
46	The crumbling of dual renin-angiotensin system blockade. <i>Current Hypertension Reports</i> , 2009 , 11, 159-161	17	
45	Cardioprotection with beta-blockers: myths, facts and Pascal's wager. <i>Journal of Internal Medicine</i> , 2009 , 266, 232-41	10.8	27
44	The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 468-70	15.1	54
43	Beta-blockers as first-line antihypertensive therapy the crumbling continues. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1162-4	15.1	15
42	The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1827-34	15.1	158
41	Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1062-72	15.1	75
40	Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1482-9	15.1	162

39	Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VERapamil SR-Trandolapril (INVEST) substudy. <i>American Heart Journal</i> , 2008 , 156, 241-7	4.9	41
38	When guidelines need guidance. <i>American Journal of Medicine</i> , 2008 , 121, 742-3	2.4	6
37	Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. <i>Circulation</i> , 2008 , 117, 2706-15; discussion 2715	16.7	100
36	βBlockers: No longer an option for uncomplicated hypertension. <i>Current Cardiovascular Risk Reports</i> , 2008 , 2, 280-285	0.9	1
35	Beta-blockers as fourth-line therapy for hypertension: stay the course. <i>International Journal of Clinical Practice</i> , 2008 , 62, 1643-6	2.9	11
34	Cardiovascular protection using beta-blockers: a critical review of the evidence. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 563-72	15.1	172
33	Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. <i>Blood Pressure</i> , 2007 , 16, 6-9	1.7	3
32	Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. <i>Hypertension</i> , 2007 , 50, 299-305	8.5	142
31	Fixed-dose combinations improve medication compliance: a meta-analysis. <i>American Journal of Medicine</i> , 2007 , 120, 713-9	2.4	758
30	Body weight changes with beta-blocker use: results from GEMINI. <i>American Journal of Medicine</i> , 2007 , 120, 610-5	2.4	70
29	Blood pressure, cognitive dysfunction, and dementia. <i>Journal of the American Society of Hypertension</i> , 2007 , 1, 135-44		11
28	Essential hypertension. <i>Lancet, The</i> , 2007 , 370, 591-603	40	435
27	Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. <i>Blood Pressure Supplement</i> , 2007 , 1, 6-9		
26	Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. <i>Annals of Internal Medicine</i> , 2006 , 144, 884-93	8	515
25	When premature is not premature—the ASCOT study. <i>European Heart Journal</i> , 2005 , 26, 1822-3	9.5	4
24	Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 1343-7	15.1	105
23	Do thiazide diuretics confer specific protection against strokes?. <i>Archives of Internal Medicine</i> , 2003 , 163, 2557-60		27
22	Evolution of calcium antagonists: past, present, and future. <i>Clinical Cardiology</i> , 2003 , 26, 112-6	3.3	20

21	A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. <i>American Journal of Medicine</i> , 2003 , 115, 41-6	2.4	574
20	A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 290, 2805-16	27.4	912
19	Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention for Endpoint Reduction in Hypertension [LIFE] Study). <i>American Journal of Cardiology</i> , 2002 , 90, 1133-4	3	6
18	Vasodilatory edema: a common side effect of antihypertensive therapy. <i>Current Cardiology Reports</i> , 2002 , 4, 479-82	4.2	97
17	Blood pressure control in stroke patients: what should the consulting neurologist advise?. <i>Neurology</i> , 2002 , 59, 23-5	6.5	20
16	Calcium antagonists in hypertension: from hemodynamics to outcomes. <i>American Journal of Hypertension</i> , 2002 , 15, 94S-97S	2.3	23
15	Antihypertensive therapy: beta-blockers and diuretics-why do physicians not always follow guidelines?. <i>Baylor University Medical Center Proceedings</i> , 2000 , 13, 128-31; discussion 131-4	0.6	8
14	Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?. <i>Archives of Internal Medicine</i> , 2000 , 160, 1905-11		46
13	Vasopeptidase inhibition and angio-oedema. <i>Lancet, The</i> , 2000 , 356, 608-9	40	170
12	Framingham at 50. <i>Lancet, The</i> , 1998 , 352, 1006	40	12
11	Comparative tolerability profile of hypertensive crisis treatments. <i>Drug Safety</i> , 1998 , 19, 99-122	5.1	50
10	Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. <i>JAMA - Journal of the American Medical Association</i> , 1998 , 279, 1903-7	27.4	368
9	Angiotensin II Receptor Inhibition. <i>Archives of Internal Medicine</i> , 1996 , 156, 1957		61
8	Introduction: antihypertensive therapy: past, present, and future. <i>Cardiovascular Drugs and Therapy</i> , 1994 , 8 Suppl 1, 7-9	3.9	
7	Antihypertensive therapy. Is it different in the elderly?. <i>Drugs</i> , 1990 , 39 Suppl 2, 49-54	12.1	6
6	Disparate cardiovascular findings in men and women with essential hypertension. <i>Annals of Internal Medicine</i> , 1987 , 107, 158-61	8	119
5	Osler's maneuver and pseudohypertension. <i>New England Journal of Medicine</i> , 1985 , 312, 1548-51	59.2	177
4	Cardiovascular pathophysiology of essential hypertension: a clue to therapy. <i>Drugs</i> , 1985 , 30 Suppl 1, 25-34	12.1	16

- | | | | |
|---|--|-----|-----|
| 3 | Arterial compliance in systolic hypertension. <i>Clinical and Experimental Hypertension</i> , 1982 , 4, 1037-44 | | 11 |
| 2 | Individualization of antihypertensive therapy: an approach based on hemodynamics and age. <i>Journal of Clinical Pharmacology</i> , 1981 , 21, 517-28 | 2.9 | 21 |
| 1 | Serum uric acid in essential hypertension: an indicator of renal vascular involvement. <i>Annals of Internal Medicine</i> , 1980 , 93, 817-21 | 8 | 295 |